News Update

Oct 01, 2001
Pharmaceutical Executive
London-European cancer patients are losing out because current processes for reviewing treatments are "dire," says the Cancer Research Campaign.
Oct 01, 2001
Pharmaceutical Executive
New York City—In response to the recent terrorist attack in its home city, Pfizer pledged nearly $10 million in aid.
Oct 01, 2001
Pharmaceutical Executive
Basel-A series of product approvals in recent weeks could go some way to compensate for setbacks in Novartis’ pipeline. The approvals came as the Swiss company reported healthy half-year figures and an 11 percent sales increase.
Oct 01, 2001
Pharmaceutical Executive
Lagos, Nigeria-FDA refused to confirm or deny that it was launching a criminal investigation into Pfizer’s conduct during a 1996 clinical trial for Trovan (alatrofloxacin) in Nigerian patients.
Oct 01, 2001
Pharmaceutical Executive
Rio de Janeiro-The Brazilian health ministry will use its $35 million a year in savings on Roche’s newly discounted AIDS therapy to fund a program aimed at providing non-AIDS medicines to low-income families.
Oct 01, 2001
Pharmaceutical Executive
Franklin Lakes, New Jersey-Merck’s pharmacy benefit arm, Merck-Medco, is under fire for switching patients to more expensive pharmaceuticals.
Sep 01, 2001
Pharmaceutical Executive
European Union-Both prescription and over-the-counter (OTC) industry sectors have welcomed the long-awaited proposals to overhaul EU pharma legislation.
Sep 01, 2001
Pharmaceutical Executive
Berlin-The German healthcare system is ailing, and politicians are too timid and inefficient to do anything about it, according to the Verband Forschender Arzneimittelhersteller (VFA), Germany’s pharmaceutical industry trade association.
Sep 01, 2001
Pharmaceutical Executive
Geneva-The usually quiet International Federation of Pharmaceutical Manufacturers Associations (IFPMA) leapt to Pfizer’s defense after Oxfam International criticized the US company about access to medicines in the developing world.
Sep 01, 2001
Pharmaceutical Executive
London-Following a review of its own drug discovery capabilities, GlaxoSmithKline practically gave away its majority stake in Affymax to a group of venture capitalists led by Patricof.
native1_300x100
lorem ipsum